Researchers track Long-Term safety of blood disorder treatment
NCT ID NCT07413679
Summary
This study aims to understand the long-term safety of adding the drug danicopan to standard treatments (eculizumab or ravulizumab) for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Researchers will analyze existing registry data from about 50 participants who are already taking this combination. The main goal is to monitor for serious side effects and infections over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Alexion Pharmaceuticals, Inc. (Sponsor)
Boston, Massachusetts, 02210, United States
Conditions
Explore the condition pages connected to this study.